

X Congreso Internacional de Investigación y Práctica Profesional en Psicología  
XXV Jornadas de Investigación XIV Encuentro de Investigadores en Psicología  
del MERCOSUR. Facultad de Psicología - Universidad de Buenos Aires, Buenos  
Aires, 2018.

# **Neurobiología, evaluación y tratamiento combinado del riesgo suicida.**

Freiria, Santiago Manuel, Ortega, Ivana, Koutsovitis, Florencia, Donatti, Sofía y Garay, Cristian Javier.

Cita:

Freiria, Santiago Manuel, Ortega, Ivana, Koutsovitis, Florencia, Donatti, Sofía y Garay, Cristian Javier (2018). *Neurobiología, evaluación y tratamiento combinado del riesgo suicida. X Congreso Internacional de Investigación y Práctica Profesional en Psicología XXV Jornadas de Investigación XIV Encuentro de Investigadores en Psicología del MERCOSUR. Facultad de Psicología - Universidad de Buenos Aires, Buenos Aires.*

Dirección estable: <https://www.aacademica.org/000-122/52>

ARK: <https://n2t.net/ark:/13683/ewym/nF4>

# NEUROBIOLOGÍA, EVALUACIÓN Y TRATAMIENTO COMBINADO DEL RIESGO SUICIDA

Freiria, Santiago Manuel; Ortega, Ivana; Koutsovitis, Florencia; Donatti, Sofía; Garay, Cristian Javier  
Universidad de Buenos Aires. Facultad de Psicología. Argentina

## RESUMEN

El suicidio es una problemática de salud pública relevante a nivel mundial y se encuentra entre las principales causas de muerte para todos los grupos etarios. Esto resalta la necesidad de evaluar características específicas que permitan su predicción, habilitando intervenciones oportunas. Entre los factores considerados se encuentran aspectos biológicos que median o moderan el riesgo suicida. Los rasgos neuropsicológicos, que representan vulnerabilidad al suicidio, son las alteraciones en la toma de decisiones y capacidades cognitivas, tratamientos biológicos, como es el caso de los antiretrovirales, la variabilidad genética de la enzima CYP2D6 y rasgos temperamentales (impulsividad, agresividad, búsqueda de novedad, labilidad afectiva y desesperanza). Así mismo, existen tratamientos farmacológicos con eficacia anti-suicida, como la Clozapina en el tratamiento de la esquizofrenia y el litio en el trastorno bipolar, abordajes que se combinan con intervenciones psicológicas. El objetivo del presente trabajo será el de revisar la bibliografía disponible con respecto a los factores neurobiológicos relacionados al riesgo suicida, reflejando las implicancias al realizar su evaluación y en la toma de decisiones con respecto a una intervención terapéutica efectiva en el contexto de los tratamientos combinados en salud mental.

## Palabras clave

Suicidio - Neurobiología - Riesgo Suicida - Evaluación - Tratamiento combinado

## ABSTRACT

### NEUROBIOLOGY, EVALUATION AND COMBINED TREATMENT OF SUICIDE RISK

Suicide is a relevant public health problem worldwide, given that it is among the leading causes of death for all age groups. This highlights the need to evaluate specific characteristics that can predict suicide risk, enabling timely interventions. Among the factors considered are biological aspects that mediate or moderate suicidal risk. The neuropsychological features, which represent vulnerability to suicide, are alterations in decision making and cognitive abilities, biological treatments, as is the case of antiretrovirals, the genetic variability of the CYP2D6 enzyme and temperamental features (impulsivity, aggressiveness, search for novelty, affective lability and hopelessness). Likewise, there are pharmacological treatments with anti-suicidal efficacy, such as clozapine in the treatment of schizophrenia and lithium in bipolar disorder, approaches that are combined with psychological interventions. The objective of this work will be to review the available literature regarding the neurobiological factors related to suicide risk, reflecting the implications

of the evaluation and making decisions regarding an effective therapeutic intervention in the context of combined treatment in the mental health field.

## Keywords

Suicide - Neurobiology - Suicide Risk - Evaluation - Combined treatment

## BIBLIOGRAFÍA

- Amiya, R.M., Poudel, K.C., Poudel-Tandukar, K., Kobayashi, J., Jimba, M. (2013). Sexually Transmitted Infections, 89, 3 -A334.
- Arie, M., Apter, A., Orbach, I., Yefet, Y., Zalzman, G. Autobiographical memory, interpersonal problem solving, and suicidal behavior in adolescent inpatients. (2008). Comprehensive Psychiatry, 49, 0-29.
- Baud, P. (2005). Personality traits as intermediary phenotypes in suicidal behavior: Genetic issues. American Journal of Medical Genetics, 133, 34-42.
- Brent, D.A., Mann, J.J. (2005). Family Genetic Studies, Suicide, and Suicidal Behavior. American Journal of Medical Genetics, 133, 13-24.
- Brent, D.A., Melhem, N. (2008). Familial Transmission of Suicidal Behavior. Psychiatric Clinics of North America, 31, 157-177.
- Brent, D.A., Melhem, N.M., Oquendo, M., Burke, A., Birmaher, B., Stanley, B., Biernesser, C., Keilp, J., Kolko, D., Ellis, S., Porta, G., Zelazny, J., Iyengar, S., Mann, J.J. (2015). Familial Pathways to Early-Onset Suicide Attempt. JAMA Psychiatry, 72, 160-168.
- Bridge, J.A., McBee-Strayer, S.M., Cannon, E.A., Sheftall, A.H., Reynolds, B., Campo, J.V., Pajer, K.A., Barbe, R.P., Brent, D.A. (2012). Impaired Decision Making in Adolescent Suicide Attempters. Journal of the American Academy of Child & Adolescent Psychiatry, 4, 394-403.
- Cipriani, A., Hawton, K., Stockton, S., Geddes, J.R. (2013). Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ Publishing Group, 346, 3646-3646.
- Collins, J.C., McFarland, B.H. (2008). Divalproex, lithium and suicide among Medicaid patients with bipolar disorder. Journal of Affective Disorders, 107, 23-28.
- John Mann, J., Ellis, S.P., Currier, D., Zelazny, J., Birmaher, B., Oquendo, M. A., Kolko, D.J., Stanley, B., Melhem, N., Burke, A.K., Brent, D.A. (2016). Self-Rated Depression Severity Relative to Clinician-Rated Depression Severity: Trait Stability and Potential Role in Familial Transmission of Suicidal Behavior. Archives of Suicide Research, 20, 1-14.
- Jollant, F., Guillaume, S., Jaussent, I., Castelnau, D., Malafosse, A., Courtet, F. Impaired decision-making in suicide attempters may increase the risk of problems in affective relationships. (2006). Journal of Affective Disorders, 99, 59-62.
- Keilp, J.G., Sackeim, H.A., Brodsky, B.S., Oquendo, M.A., Malone, K.M., Mann, J. (2001). Neuropsychological Dysfunction in Depressed Suicide Attempters. American Journal of Psychiatry, 158, 735-741.

- Lopez-Castroman, J., Jaussent, I., Beziat, S., Genty, C., Olie, E., de Leon-Martinez, V., Baca-Garcia, E., Malafosse, A., Courtet, P., Guillaume, S. (2012). Research report Suicidal phenotypes associated with family history of suicidal behavior and early traumatic experiences. *Journal of Affective Disorders*, 142, 193-199.
- McGirr, A., Renaud, J., Bureau, A., Seguin, M., Lesage, A., Turecki, G. (2008). Impulsive-aggressive behaviours and completed suicide across the life cycle: a predisposition for younger age of suicide. *Psychological Medicine*, 38, 407-417.
- Meltzer, H.Y. (2003). Clozapine Treatment for Suicidality in Schizophrenia. *Archives of General Psychiatry*, 60, 82-91.
- Novakovic, V., Sher, L. (2012). The use of clozapine for the treatment of schizophrenia and implications for suicide prevention. *International Journal on Disability and Human Development*, 11, 5-8.
- Peñas-Lledó, E., Guillaume, S., Naranjo, M.E.G., Delgado, A., Jaussent, I., Blasco-Fontecilla, H., Courtet, P. & L. Lerena, A. (2015). A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. *The pharmacogenomics journal*, 15 (2), 172-176.
- Ringbäck Weitoft, G., Berglund, M., Lindström, E. A., Nilsson, M., Salmi, P., & Rosén, M. (2014). Mortality, attempted suicide, re-; hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden—a register-based study. *Pharmacoepidemiology and drug safety*, 23(3), 290-298.
- Roy, A. (2011). Combination of family history of suicidal behavior and childhood trauma may represent correlate of increased suicide risk. *Journal of Affective Disorders*, 130, 205- 208.
- Serafini, G., Solano, P., & Amore, M. (2016). Antidepressant Medications and Suicide Risk: What Was the Impact of FDA Warning?. In López-Muñoz, F., Srinivasan, V., de Berardis, D., Álamo, C., Kato, T.A. (Eds.), *Melatonin, Neuroprotective Agents and Antidepressant Therapy* (pp. 477-499). Springer, New Delhi.
- Smith, E. G., Søndergård, L., Lopez, A.G., Andersen, P. K., & Kessing, L.V. (2009). Association between consistent purchase of anticonvulsants or lithium and suicide risk: A longitudinal cohort study from Denmark, 1995–2001. *Journal of affective disorders*, 117(3), 162-167.
- Takeshi, T., Shinjiro, G., Masatoshi, I., Yasumasa, O. Even very low but sustained lithium intake can prevent suicide in the general population? *Medical Hypotheses*, 73, 811-812.